With H1 2019 sales growth of 33% and double digit profit margin, Zhongchao could represent a magnificent opportunity for growth investors.
It holds a significant amount of cash to finance future growth and a very small amount of debt. The investors believing in the future growth of China and willing to invest in the healthcare sector will definitely like this name.
It is still a small company and not that well-known, thus market participants need to review its financials before the whole market does so.
Buy our 10 pages analysis for just $29!
—
Previous Financial Analysis:
# Equity Research Report: BANGI, Inc. (OTCMKTS: BNGI) Growing Through Acquisitions
# Lennox International (NYSE: LII): We Don’t Like The Accumulation Of Inventory
Disclosure: We hold no position in Zhongchao, BNGI and LII either long or short, and we have not been compensated for the research.
